Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer

Bone

Volumn 55, Issue 2, 2013, Pages 305-308

  Milat, F ^a,b   Goh, S ^a   Gani, L U ^a   Suriadi, C ^c   Gillespie, M T ^a,b   Fuller, P J ^a,b   Teede, H J ^a,b   Strickland, A H ^c   Allan, C A ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Monash Cancer Centre   (Australia)

Author keywords

Bone; Denosumab; Hypocalcemia; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BICALUTAMIDE; CABAZITAXEL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; CREATININE; DENOSUMAB; DOCETAXEL; GLUCONATE CALCIUM; GOSERELIN; PHOSPHORUS; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CHVOSTEK SIGN; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMUR NECK FRACTURE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LETHARGY; LYMPH NODE METASTASIS; MALE; MEDICAL HISTORY; MUSCLE TWITCH; MUSCULOSKELETAL SYSTEM PARAMETERS; PALLIATIVE THERAPY; PATIENT MONITORING; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; SPINAL CORD METASTASIS; TREATMENT DURATION; TROUSSEAU SIGN; URINE RETENTION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; HUMANS; HYPOCALCEMIA; MALE; PROSTATIC NEOPLASMS;

EID: 84878142363     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.04.012     Document Type: Article

References (15)

1. Yuasa T., Yamamoto S., Urakami S., Fukui I., Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther 2012, 5:221-229.
2. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
3. Fizazi K., Carducci M., Smith M., Damiao R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
4. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
5. Lipton A., Fizazi K., Stopeck A.T., Henry D.H., Brown J.E., Yardley D.A., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3092.
6. Michael R., McClung M.D., Michael E., Lewiecki M.D., et al. Denosumab in postmenopausal women with low bone density. N Engl J Med 2006, 354:821-831. (February 23).
7. XGEVA® (denosumab) Approved Product Information http://www.amgen.com.au/Xgeva.PI.
8. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
9. Henry D.H., Costa L., Goldwasser F., Hirsh V., Hungria V., Prausova J., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
10. Ludwid G.D. Hypocalcaemia and hypophosphataemia accompaning osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function. Ann Intern Med 1962, 676-677.
11. Murray R.M., Grill V., Crinis N., Ho P.W., Davison J., Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001, 86:4133-4138.
12. Peter R., Mishra V., Fraser W.D. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004, 328:335-336.
13. Ho J.W., Sundar S. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?. Clin Genitourin Cancer 2012, 10:50-53.
14. Gulley J.L., Wu S., Arlen P.M., Dahut W.L. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer 2007, 5:403-405.
15. McCormick B.B., Davis J., Burns K.D. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012, 60:626-628.